1)Camacho PM, et al:American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract 26:1-46, 2020
2)骨粗鬆症の予防と治療ガイドライン作成委員会(編):骨粗鬆症の予防と治療ガイドライン2015年版,ライフサイエンス出版,2015
3)Kanis JA, et al:Smoking and fracture risk;A meta-analysis. Osteoporos Int 16:155-162, 2005
4)Kanis JA, et al:Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737-742, 2005
5)Michaëlsson K, et al:Long term calcium intake and rates of all cause and cardiovascular mortality;Community based prospective longitudinal cohort study. BMJ 346:f228, 2013
6)Sato M, et al:Treatment for osteoporosis among women in Japan;Associations with patient characteristics and patient-reported outcomes in the 2008-2011 Japan National Health and Wellness Surveys. J Osteoporos 2014:909153, 2014
7)厚生労働省.骨粗鬆症治療薬の薬剤料の推移等について. https://www.mhlw.go.jp/bunya/iryouhoken/database/zenpan/dl/cyouzai_doukou_topics_h31_03-02.pdf(2023年2月閲覧)
analog, eldecalcitol, prevents the risk of osteoporotic fractures;A randomized, active comparator, double-blind study. Bone 49:605-612, 2011
9)Black DM, et al:Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383:743-753, 2020
10)Reid IR, et al:Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 379:2407-2416, 2018